2024
Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
Da X, Hempel E, Ou Y, Rowe O, Malchano Z, Hajós M, Kern R, Megerian J, Cimenser A. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease. Journal Of Alzheimer's Disease 2024, 97: 359-372. PMID: 38073386, PMCID: PMC10789351, DOI: 10.3233/jad-230506.Peer-Reviewed Original ResearchConceptsWhite matter atrophyActive treatment participantsMatter atrophyAlzheimer's diseaseMyelin lossTreatment participantsWhite matterNeuronal network functionT2-weighted MRIEarly disease interventionMRI outcomesClinical trialsEntorhinal regionWhite matter structuresHz stimulationMagnetic resonance imaging dataAfferent connectionsInclusion criteriaTherapeutic approachesAtrophySensory stimulationVolume assessmentDisease interventionDiseaseMyelin content
2023
Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease
Hajos M, Boasso A, Cimenser A, Shpokayte M, Hempel E, Da X, Seshagiri C, Megerian J, Vaughan B, Malchano Z. Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.072957.Peer-Reviewed Original ResearchClinical trialsAlzheimer's diseaseActive armPotential novel therapeutic interventionsSensory stimulationOccipital cortical thicknessAmyloid plaque loadAbnormal neuronal activityPivotal clinical trialsStimulation systemPromising treatment optionDifferent therapeutic approachesNovel therapeutic interventionsMinimal side effectsQuantitative MRI analysisNeuronal network oscillationsDaily therapyPlaque loadADCS-ADLBrain atrophyClinical presentationTreatment armsClinical benefitClinical efficacyAD pathologyDecay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation
Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M, Cimenser A. Decay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077337.Peer-Reviewed Original ResearchMagnetic resonance imagingEntorhinal regionAlzheimer's diseaseWhite matterPlacebo groupDisease patientsMRI measuresTreatment groupsPlacebo-controlled feasibility studyPhase I/IISensory stimulationMonth 6 visitMonths of treatmentStructural magnetic resonance imagingAlzheimer's disease patientsSignal intensityT1 magnetic resonance imagingLinear mixed-effects modelingMonth 3WM atrophyMyelin lossAD severityWM/GM contrastMixed-effects modelingAD patientsA Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s Disease
Boasso A, Houser C, Hajos M, Newberger J, Seshagiri C, Leach J, Konisky A, Galley A, Hempel E, Dickson S, Hendrix S, Malchano Z, Megerian J. A Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.080670.Peer-Reviewed Original ResearchMini-Mental State ExamClinical Dementia Rating ScaleZarit Burden IndexPivotal trialsSensory stimulationAlzheimer's Disease Cooperative Study-ActivitiesConcurrent medication useOccipital cortical thicknessKey secondary outcomesProspective clinical trialsPrimary outcome measureSelf-administered therapyClinical laboratory assessmentsClinical efficacy assessmentBrain structural changesDaily living testDementia Rating ScaleSubgroup of subjectsMental State ExamAlzheimer's disease symptomsHOPE trialSecondary outcomesAdverse eventsMedication useADCS-ADL
2022
Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004)
Cimenser A, Mrozak H, Da X, Travers T, Hempel E, Seshagiri C, Boasso A, Vaughan B, Megerian J, Malchano Z, Hajos M. Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1799.Peer-Reviewed Original ResearchFeasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001)
Megerian J, Hajos M, Hempel E, Cimenser A, Boasso A, Cotter C, Williams M, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Malchano Z. Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1936.Peer-Reviewed Original Research